LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 29 of 66
Next
>>
>
701 to 725 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Dasatinib	180619_MC_12	1193	0.1832	139	105	9	4	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_8	244	0.1698	635.9	71.1	15071	356.7	0.0231	0.14672	0.1477
Dasatinib	180619_MC_12	1897	0.1404	104	177	12	11	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_9	281	0.1290	635.9	71.1	15071	356.7	0.0231	0.10594	0.2704
Dasatinib	180619_MC_10	706	0.3611	86	200	7	20	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_1	286	0.2883	635.9	71.1	15071	356.7	0.0231	0.26523	0.0232
Dasatinib	180619_MC_10	488	0.3676	56	144	12	3	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_2	200	0.2907	635.9	71.1	15071	356.7	0.0231	0.26762	-0.0563
Dasatinib	180619_MC_10	839	0.2393	51	162	13	9	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_3	213	0.2025	635.9	71.1	15071	356.7	0.0231	0.17940	0.0626
Dasatinib	180619_MC_11	762	0.2769	47	177	12	8	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_4	224	0.2272	635.9	71.1	15071	356.7	0.0231	0.20411	0.0404
Dasatinib	180619_MC_11	967	0.2287	65	171	13	20	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_5	236	0.1962	635.9	71.1	15071	356.7	0.0231	0.17310	0.0961
Dasatinib	180619_MC_11	793	0.2867	65	181	13	22	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_6	246	0.2368	635.9	71.1	15071	356.7	0.0231	0.21369	0.0495
Dasatinib	180619_MC_12	906	0.3118	162	171	3	13	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_7	333	0.2688	635.9	71.1	15071	356.7	0.0231	0.24569	0.0806
Dasatinib	180619_MC_12	944	0.2570	95	172	4	11	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_8	267	0.2205	635.9	71.1	15071	356.7	0.0231	0.19740	0.0904
Dasatinib	180619_MC_12	884	0.2809	127	157	11	11	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_9	284	0.2432	635.9	71.1	15071	356.7	0.0231	0.22008	0.0748
Dasatinib	180619_MC_10	298	0.9678	106	285	4	13	Dasatinib	9.98	treatment	72	2	MCF10A-GM_1	391	0.5675	635.9	71.1	15071	356.7	0.0231	0.54441	-0.1529
Dasatinib	180619_MC_10	274	0.9823	121	267	7	11	Dasatinib	9.98	treatment	72	2	MCF10A-GM_2	388	0.5861	635.9	71.1	15071	356.7	0.0231	0.56303	-0.1684
Dasatinib	180619_MC_10	287	0.9156	116	253	8	19	Dasatinib	9.98	treatment	72	2	MCF10A-GM_3	369	0.5625	635.9	71.1	15071	356.7	0.0231	0.53943	-0.1599
Dasatinib	180619_MC_11	328	0.8231	96	253	6	4	Dasatinib	9.98	treatment	72	2	MCF10A-GM_4	349	0.5155	635.9	71.1	15071	356.7	0.0231	0.49244	-0.1349
Dasatinib	180619_MC_11	283	0.9894	190	278	7	19	Dasatinib	9.98	treatment	72	2	MCF10A-GM_5	468	0.6232	635.9	71.1	15071	356.7	0.0231	0.60009	-0.1624
Dasatinib	180619_MC_11	273	0.9044	93	238	12	19	Dasatinib	9.98	treatment	72	2	MCF10A-GM_6	331	0.5480	635.9	71.1	15071	356.7	0.0231	0.52494	-0.1690
Dasatinib	180619_MC_12	231	0.9471	185	209	5	8	Dasatinib	9.98	treatment	72	2	MCF10A-GM_7	394	0.6304	635.9	71.1	15071	356.7	0.0231	0.60733	-0.1989
Dasatinib	180619_MC_12	261	0.9365	196	232	7	16	Dasatinib	9.98	treatment	72	2	MCF10A-GM_8	428	0.6212	635.9	71.1	15071	356.7	0.0231	0.59812	-0.1772
Dasatinib	180619_MC_12	284	0.8345	127	216	11	16	Dasatinib	9.98	treatment	72	2	MCF10A-GM_9	343	0.5470	635.9	71.1	15071	356.7	0.0231	0.52398	-0.1618
Etoposide	180619_MC_10	15497	0.0178	19	257	4	7	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_1	276	0.0175	635.9	71.1	15071	356.7	0.0231	-0.00558	1.0122
Etoposide	180619_MC_10	14749	0.0208	56	252	5	10	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_2	308	0.0205	635.9	71.1	15071	356.7	0.0231	-0.00262	0.9906
Etoposide	180619_MC_10	13248	0.0216	46	241	12	10	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_3	287	0.0212	635.9	71.1	15071	356.7	0.0231	-0.00187	0.9443
Etoposide	180619_MC_11	14372	0.0221	78	241	10	3	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_4	319	0.0217	635.9	71.1	15071	356.7	0.0231	-0.00136	0.9793
Etoposide	180619_MC_11	15289	0.0225	54	291	10	20	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_5	345	0.0221	635.9	71.1	15071	356.7	0.0231	-0.00101	1.0063

|<
<<
Previous
Page 29 of 66
Next
>>
>
701 to 725 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)